Here you can find resources to download and access related to VOYDEYA®1 (danicopan) as an add-on to ULTOMIRIS®2 (ravulizumab) or SOLIRIS®3 (eculizumab) for the treatment of adult patients with Paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.
Please click the links below to be redirected to a third-party website, where you can access and find more information on these selected publications.
*Currently, the explanation offered for greater severity of breakthrough IVH with escape from proximal monotherapy blockade vs escape from C5 blockade is theoretical.
Alexion is not the copyright holder of either the journal or the articles – such copyright(s) is/are held by the publisher(s) and/or the author(s) of the journal and/or article as appropriate. Alexion has provided the weblinks to the full article(s) merely to assist the reader and on the basis that the relevant article(s) is/are either available as ‘open access’ or via a subscription service which the reader may already subscribe to. Alexion assumes no responsibility for ascertaining if the reader has appropriate copyright licence for use of the relevant article and Alexion makes no attempt to provide any licence or permission to the reader – all such permissions and ownership rest exclusively with their owners.
Adverse Event Reporting
Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion,AstraZeneca Rare Disease by contacting: https://contactazmedical.astrazeneca.com/
For more information on ULTOMIRIS®, VOYDEYA® and/or SOLIRIS®, please refer to the relevant SmPCs.1–3
PNH, Paroxysmal nocturnal haemoglobinuria.
PNH, Paroxysmal nocturnal haemoglobinuria.
healthcare professional